Ubs Asset Management Americas Inc Zentalis Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 113,386 shares of ZNTL stock, worth $416,126. This represents 0.0% of its overall portfolio holdings.
Number of Shares
113,386
Previous 67,472
68.05%
Holding current value
$416,126
Previous $1.06 Million
56.44%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ZNTL
# of Institutions
148Shares Held
69.8MCall Options Held
61.8KPut Options Held
6.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$51.2 Million0.43% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$31.4 Million0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.65MShares$20.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$17.7 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.5MShares$16.5 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $209M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...